Significant extension of OS Pfizer/Astellaxtandi treatment nmCRPC Phase III results announced

Prosper is a large-scale, randomized, double-blind, placebo-controlled, multi-country study that enrolled approximately 1,400 nmCRPC patients in the United States, Canada, Europe, South America, and Asia Pacific to assess the efficacy and safety of Xtandi (160 mg, once-daily orally) and placebo-combined androgen deprivation therapy (ADT) therapyIn this study, the primary endpoint was no transfer lifetime (MFS) and the critical secondary endpoint was total lifetime (OS)previously published results showed that xtandi-ADT significantly reduced the risk of metastasis or death by 71% compared to placebo-ADT: 23% of patients in the Xtandi-ADT treatment group had metastasis or death, compared with 49% in the placebo-ADT treatment groupThe main endpoint of the study, MFS, was 14.7 months in the placebo-ADT treatment group and 36.6 months in the Xtandi-ADT treatment group, with an extension of 22 months (HR-0.29(95% CI:0.24-0.35), p 0.001)The final results of the OS analysis published: Xtandi-ADT treatment group had a 27% reduction in the risk of death compared to the placebo-ADT treatment group (HR-0.73; 95% CI: 0.61-0.89; p-0.001), significantly extended total lifetime (median OS: 67.0 months (95% CI: 64.0-not reached) vs56.3 months (95% CI: 54.5-63.0) ) , with statistically significant differences in the dataIn this analysis, adverse events are consistent with previous reportsGlobally, prostate cancer is the second leading cause of death in men after lung cancerProstate cancer usually occurs in older age groups and is often triggered by excess male hormones (including testosterone, or androgens), and the conventional clinical treatment is to lower androgen levels (degenerative), which can be achieved through surgical de-sepsis and/or androgen deprivation therapy (ADT)metastatic prostate cancer is where cancer cells have spread to other parts of the body outside the prostate (such as bones, lymph nodes, bladder, and rectum) and is considered hormone (or desperation) if the patient is still reacting to surgery or medication that lowers testosterone levels, and hormone (or descoym) resistance if it does notXtandi (Ancotan, Nzalaamine) was developed and sold by Astellas in conjunction with Pfizer, a androgen receptor signaling inhibitor that is taken dailyXtandi directly targets androgen receptors (ARs) and plays a role in three steps along ar signaling: (1) inhibiting androgen binding - androgen binding induces conformation altogether changes that trigger receptor activation;Xtandi was launched in 2012 and has so far been approved for three treatments for the conditions of prostate cancer( metastatic resistance prostate cancer (mCRPC, August 2012), non-metastatic resistance prostate cancer (nmCRPC, July 2018), metastatic desacist prostate cancer (mCSPC, December 2019)In particular, Xtandi is now the first and only product approved for the treatment of three unique types of advanced prostate cancer (nmCRPC, mCRPC, mCSPC)Xtandi: A Big Mac product in the prostate cancer sector, with sales of $4.2 billion in 2019, has been marketed in China
in China, and Xtandi was approved at the end of November 2019 for treatment of adult patients with mCRPC who have no symptoms or mild symptoms after ADT failure and who have not undergone chemotherapy Prostate cancer is the second most common malignant tumor in men in the world, and has become the most common male urinary malignant tumor in China Xtandi is the world's best-selling prostate cancer drug Xtandi's full-year sales were $838 million, according to Pfizer's 2019 results Xtandi's sales were $655 million and $2,711 million from January 31, 2019 to April 31, 2018 (q4 fY18), April 31, 2019 to January 31, 2019 (the first three quarters of fiscal year 2019), according to the results report released by Astellas On this basis, Xtandi's global sales reached $4.202 billion in 2019 as part of a clinical development project in the field of prostate cancer, Pfizer and Astellas are also currently conducting another Phase III clinical study, EMBARK ( registration number: NCT02319837), to assess the therapeutic potential of Xtandi-Brightrelin combination therapy, Xtandi monodruga therapy, compared to the monotherapy of monotherapy in 1068 high-risk non-metastatic hormone-sensitive prostate cancer (nmCSPC) male patients original origin: Final Prosper Results Show XTANDI ® (enzalutamide) Significantly Extends STakes 66 Survival Sin Non-Metastatic Caststatic-Resistant Prostate Cancer original title: Pfizer/Anstella Xtandi treatment non-meta-destotic (nmCRPC) significantly extended total survival, China is available!